BLPH News and Press, Bellerophon Therapeutics Inc. From 05/04/20

WARREN, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that Fabian Tenenbaum, Chief Executive Officer of Bellerophon, will participa...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

CounterPath (NASDAQ: CPAH ) +91%  on Q4 update . More news on: CounterPath Corporation, Borqs Technologies, Inc., Immunomedics, Inc., Stocks on the move, Read more ...

Sonnet BioTherapeutics Holdings (NASDAQ: SONN ) +100% . More news on: Sonnet BioTherapeutics Holdings, Inc., MEI Pharma, Inc., NantKwest, Inc., Stocks on the move, Read more ...

Axsome Therapeutics (NASDAQ: AXSM ) initiated with Outperform rating and $95 (58% upside) price target at Cowen and Company. More news on: Axsome Therapeutics, Inc., Bellerophon Therapeutics, Inc., HealthEquity, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Mesoblast Gets FDA Go-Ahead for COVID 19 Treatment Application Mesoblast Limited ( MESO ) announced that the US FDA has cleared its Investigational New Drug application for treating patients suffering from acute respiratory distress syndrome ((ARDS)) due to coronavirus infection using re...

WARREN, N.J., April 08, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced the submission of an Investigational New Drug (IND) application to the U.S....

The United States has a critical shortage of ventilators as it battles the coronavirus outbreak. One small cap biotech company by the name of Bellerophon Therapeutics, Inc. (BLPH) may have a novel solution to help alleviate the demand for ventilators. The FDA recently granted the company Eme...

Bellerophon Therapeutics (NASDAQ: BLPH ): Q4 GAAP EPS of -$0.89  misses by $0.33 . More news on: Bellerophon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

WARREN, N.J., April 06, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the fourth quar...